Abiraterone acetate

Nature Reviews Drug Discovery

Volumn 10, Issue 8, 2011, Pages 573-574

  Logothetis, Christopher J ^a   Efstathiou, Eleni ^a   Manuguid, Fil ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BEVACIZUMAB; CABAZITAXEL; DASATINIB; DOCETAXEL; GONADORELIN; JAVTANA; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SUNITINIB; TESTOSTERONE; UNCLASSIFIED DRUG; ZYTIGA;

ANDROGEN SYNTHESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TUMOR MICROENVIRONMENT;

ANDROSTENOLS; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 79960980460     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3516     Document Type: Article

References (7)

1. Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241-1246 (2005). (Pubitemid 41743917)
3. Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867-3875 (2011).
4. Potter, G. A. et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463-2471 (1995).
5. US Food and Drug Administration. FDA labeling information-Zytiga. FDA website [online], http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/ 202379lbl.pdf (2011).
6. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
7. Efstathiou, E, & Logothetis, C. J. A new therapy paradigm for prostate cancer founded on clinical observations. Clin. Cancer Res. 16, 1100-1107 (2010).